A Phase 3 interventional study of rMenB+OMV NZ in Prevention of the Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-08.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 21st largest by enrollment, is the only one that started in 2013, is one of 7 in phase 3, and was the 11th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
60 studies in Meningococcal Infections by Novartis: none open now, none under way, none of them phase 3. Of 59 finished, 48 (81%) have results posted.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 57th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2013, is one of 27 in phase 3, and was the 55th registered.
Novartis’s Meningococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 60 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the immunogenicity and safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sponsor's employees are considered eligible to participate in the trial as per inclusion criteria.
Exclusion Criteria:
Known or suspected disease or impairment/alteration of the immune system resulting from (for example):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
Biological: rMenB+OMV NZ
Drug page: 4CMenB vaccine
Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule
The immunogenicity was assessed to evaluate the human serum bactericidal activity (hSBA) against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and M10713 strain at baseline and at one month after the second vaccination.
Time frame: Day1 and Day 91
Geometric Mean Ratios Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule
The immunogenicity was assessed to evaluate the hSBA in terms of geometric mean ratios within subjects against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 at one month after the second vaccination versus baseline.
Time frame: Day1 and Day 91
Percentages Of Subjects With hSBA≥ 1:5 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.
The immunogenicity was assessed to evaluate the hSBA titers ≥ 1:5 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.
Time frame: Day1 and Day91
Percentages Of Subjects With hSBA≥ 1:8 Titers Against N Meningitidis Serogroup B Strains Following Two-Dose Vaccination Schedule.
The immunogenicity was assessed to evaluate the human serum bactericidal activity titers ≥ 1:8 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.
Time frame: Day1 and Day91
Percentages Of Subjects With Four-Fold Increase In Human Serum Bactericidal Activity From Baseline Against N Meningitidis Serogroup B Strains Following a Two Dose Vaccination Schedule.
The antibody responses were assessed to evaluate the four fold increase in human serum bactericidal activity titers in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.
Time frame: Day 91
Geometric Mean Concentrations For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule
The antibody responses were assessed to evaluate the geometric mean concentrations as measured by Enzyme Linked Immunosorbent Assay (ELISA) in terms of percentages of subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at baseline and at one month the second vaccination.
Time frame: Day 1 and Day 91
Geometric Mean Ratios For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.
The antibody responses were assessed to evaluate the geometric mean ratios as measured by ELISA within the subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month after the second vaccination versus baseline.
Time frame: Day 1 and Day 91
Percentages of Subjects With Four Fold Increase From Baseline For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule.
The antibody responses were assessed to evaluate the four fold increases in ELISA concentrations as measured by ELISA to the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month the second vaccination over baseline.
Time frame: Day 1 and Day 91
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination)
The number of subjects with solicited local and systemic adverse events after receiving rMenB+OMV NZ (a two dose vaccination schedule) collected from day 1 through day 7 are reported.
Time frame: Day 1 through Day 7 postvaccination.
Number of Subjects Reporting Unsolicited Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).
Safety was assessed as the number of subjects who reported unsolicited adverse events as collected from Day 1 to Day 91 following rMenB+OMV vaccination (a two dose schedule). Unsolicited adverse events were collected from day 1 through day 7 after each vaccination, while serious adverse events, medically attended adverse events and adverse events leading to withdrawal from study were reported from day 1 through day 91.
Time frame: Day 1 through Day 91 postvaccination.
Number of Subjects Reporting Unsolicited Serious Adverse Events After Receiving rMenB+OMV NZ Vaccine ( After Any Vaccination).
Safety was assessed as the number of subjects who reported Serious Adverse Events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, as collected from day 1 to day 91 following vaccination with rMenB+OMV NZ (a two dose schedule ) are reported.
Time frame: Day 1 through Day 91 postvaccination.
Subjects were recruited from single study center in Germany.
| Milestone | rMenB+OMV NZ |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
The immunogenicity was assessed to evaluate the human serum bactericidal activity (hSBA) against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and M10713 strain at baseline and at one month after the second vaccination.
| Titers | rMenB+OMV NZ |
|---|---|
| H44/76 Prevaccination (Day 1) | 1.18 (0.92 to 1.52) |
| Post 2nd vaccination (Day 91) | 53 (34 to 84) |
| 5/99 Prevaccination (Day 1) | 2.27 (1.34 to 3.85) |
| After 2nd vaccination (Day 91)(N=12) | 143 (57 to 356) |
| NZ98/254 Prevaccination (Day 1) | 1.09 (0.91 to 1.31) |
| Post 2nd vaccination (Day 91)(N=12) | 15 (5.41 to 43) |
| M10713 Prevaccination (Day 1) | 21 (12 to 39) |
| Post second vaccination (Day 91)(N=12) | 56 (31 to 99) |
The immunogenicity was assessed to evaluate the hSBA in terms of geometric mean ratios within subjects against the indicator strains of N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 at one month after the second vaccination versus baseline.
| ratio | rMenB+OMV NZ |
|---|---|
| H44/76 (Day 91/Day 1) | 45 (29 to 70) |
| 5/99 (Day 91/Day 1)(N=12) | 59 (21 to 166) |
| NZ98/254 (Day 91/Day 1)(N=12) | 14 (5.17 to 37) |
| M10713 (Day 91/Day 1)(N=12) | 2.99 (1.43 to 6.27) |
The immunogenicity was assessed to evaluate the hSBA titers ≥ 1:5 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.
| Percentages of subjects | rMenB+OMV NZ |
|---|---|
| H44/76 Prevaccination (Day 1) | 0 (0 to 25) |
| Post 2nd vaccination (Day 91) | 100 (75 to 100) |
| 5/99 Prevaccination (Day 1) | 31 (9 to 61) |
| After 2nd vaccination (Day 91)(N=12) | 100 (74 to 100) |
| NZ98/254 Prevaccination (Day 1) | 0 (0 to 25) |
| Post 2nd vaccination (Day 91)(N=12) | 75 (43 to 95) |
| M10713 Prevaccination (Day 1) | 92 (64 to 100) |
| Post second vaccination (Day 91)(N=12) | 100 (74 to 100) |
The immunogenicity was assessed to evaluate the human serum bactericidal activity titers ≥ 1:8 in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.
| Percentage of Subjects | rMenB+OMV NZ |
|---|---|
| H44/76 Prevaccination (Day 1) | 0 (0 to 25) |
| Post 2nd vaccination (Day 91) | 100 (75 to 100) |
| 5/99 Prevaccination (Day 1) | 8 (0 to 36) |
| After 2nd vaccination (Day 91)(N=12) | 92 (62 to 100) |
| NZ98/254 Prevaccination (Day 1) | 0 (0 to 25) |
| Post 2nd vaccination (Day 91)(N=12) | 75 (43 to 95) |
| M10713 Prevaccination (Day 1) | 85 (55 to 98) |
| Post second vaccination (Day 91)(N=12) | 92 (62 to 100) |
The antibody responses were assessed to evaluate the four fold increase in human serum bactericidal activity titers in terms of percentages of subjects against N meningitidis serogroup B (H44/76, 5/99, NZ98/254) and strain M10713 following a two dose vaccination schedule with rMenB+OMV NZ vaccine.
| Percentage of subjects | rMenB+OMV NZ |
|---|---|
| H44/76 | 100 (75 to 100) |
| 5/99 (N=12) | 92 (62 to 100) |
| NZ98/254 (N=12) | 75 (43 to 95) |
| M10713 (N=12) | 33 (10 to 65) |
The antibody responses were assessed to evaluate the geometric mean concentrations as measured by Enzyme Linked Immunosorbent Assay (ELISA) in terms of percentages of subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at baseline and at one month the second vaccination.
| U/mL | rMenB+OMV NZ |
|---|---|
| Prevaccination (Day 1) | 22 (18 to 28) |
| Post second vaccination (Day 91) | 1200 (537 to 2680) |
The antibody responses were assessed to evaluate the geometric mean ratios as measured by ELISA within the subjects for the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month after the second vaccination versus baseline.
| Ratio | rMenB+OMV NZ |
|---|---|
| Geometric Mean Ratios For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule. | 54 (24 to 120) |
The antibody responses were assessed to evaluate the four fold increases in ELISA concentrations as measured by ELISA to the vaccine antigen 287-953 following a two dose vaccination schedule with rMenB+OMV NZ vaccine at one month the second vaccination over baseline.
| Percentage of Subjects | rMenB+OMV NZ |
|---|---|
| Percentages of Subjects With Four Fold Increase From Baseline For Vaccine Antigen 287-953 Following A Two-dose Vaccination Schedule. | 85 (55 to 98) |
The number of subjects with solicited local and systemic adverse events after receiving rMenB+OMV NZ (a two dose vaccination schedule) collected from day 1 through day 7 are reported.
| Number of Subjects | rMenB+OMV NZ |
|---|---|
| Any local | 13 |
| Injection site erythema | 0 |
| Injection site swelling | 0 |
| Injection site induration | 1 |
| Injection site pain | 13 |
| Any Systemic | 9 |
| Nausea | 2 |
| Myalgia | 3 |
| Arthralgia | 3 |
| Fatigue | 5 |
| Headache | 8 |
| Fever (≥38°C) | 1 |
| Prophylactic use of antipyretics/analgesics | 0 |
| Therapeutic use of antipyretics/analgesics | 4 |
Safety was assessed as the number of subjects who reported unsolicited adverse events as collected from Day 1 to Day 91 following rMenB+OMV vaccination (a two dose schedule). Unsolicited adverse events were collected from day 1 through day 7 after each vaccination, while serious adverse events, medically attended adverse events and adverse events leading to withdrawal from study were reported from day 1 through day 91.
| Number of subjects | rMenB+OMV NZ |
|---|---|
| Any unsolicited AEs | 8 |
| At least possibly related unsolicited AEs | 7 |
Safety was assessed as the number of subjects who reported Serious Adverse Events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, as collected from day 1 to day 91 following vaccination with rMenB+OMV NZ (a two dose schedule ) are reported.
| Number of subjects | rMenB+OMV NZ |
|---|---|
| AEs leading to study withdrawal | 0 |
| Medically attended AEs | 2 |
| Any SAEs | 0 |
| At least possibly related SAEs | 0 |
| AEs leading to death | 0 |
Collected over Day 1 through Day 91 postvaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB+OMVNZ | — | 0/13 (0%) | 13/13 (100%) |
| Event | rMenB+OMVNZ |
|---|---|
| INJECTION SITE PAINGeneral disorders | 13/13 |
| INJECTION SITE ERYTHEMAGeneral disorders | 10/13 |
| HEADACHENervous system disorders | 8/13 |
| FATIGUEGeneral disorders | 5/13 |
| INJECTION SITE INDURATIONGeneral disorders | 5/13 |
| INJECTION SITE SWELLINGGeneral disorders | 5/13 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 3/13 |
| MYALGIAMusculoskeletal and connective tissue disorders | 3/13 |
| NAUSEAGastrointestinal disorders | 2/13 |
| RESPIRATORY TRACT INFECTIONInfections and infestations | 2/13 |
Subjects received two doses of rMenB+OMV NZ at 0 month and 2 month schedule.
| Age, Continuous(year) | rMenB+OMV NZ |
|---|---|
| Mean | 38.5 ± 12.2 |
| Sex: Female, Male(Participants) | rMenB+OMV NZ |
|---|---|
| FEMALE | 10 |
| MALE | 3 |
The record gives a start of Aug 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine